A

Atea Pharmaceuticals
D

AVIR

3.29000
USD
0.09
(2.65%)
مفتوح الان
حجم التداول
1,952
الربح لكل سهم
0
العائد الربحي
-
P/E
-2
حجم السوق
277,883,464
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ABUS
    0.00500
    (0.16%)
    3.20500 USD
    A
    ADAP
    -0.01120
    (-1.87%)
    0.58850 USD
    A
    ASND
    1.190
    (0.87%)
    137.300 USD
    C
    CRNC
    0.02500
    (0.33%)
    7.70000 USD
    G
    GERN
    -0.12500
    (-3.56%)
    3.38500 USD
    I
    ICHR
    0.900
    (3.01%)
    30.760 USD
    N
    NVAX
    -0.13000
    (-1.49%)
    8.59000 USD
    X
    XENE
    -0.170
    (-0.44%)
    38.420 USD
    المزيد
الأخبار
المقالات

العنوان: Atea Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).